Imagion Biosystems
Limited, an Australian firm dedicated to improving healthcare through early
detection and research for diseases like cancer by using the latest diagnostic
imaging technology, has recently obtained a patent from India. By bringing
biotechnology and nanotechnology together, Imagion aims to recognize cancer and
other diseases earlier, thus making it possible for the patient to recover at
the early stages.
The recent patent –
#320872 – from the Indian Patent Office has been issued for the company’s
core Intellectual Property (IP) associated with detection,
analysis, and imaging of diseases by using magnetic nanoparticles. The new
patent has added India to the Imagion’s existing global market coverage,
including Australia, Israel, Russia, Japan, and the US. And, if we talk about
the term of this newly issued Indian patent, then it extends to the year 2030.
As per the data
provided by the International Agency for Research on Cancer, the number of
patients getting a diagnosis of this disease in India is expected to increase
to 1.41 million by 2026 from 1.15 million in 2018. Alongside these statistics,
the Indian Council of Medical Research abbreviated as ICMR has reported that
lung cancer and breast cancer are the two most common cancers from which the
residents in the country often suffer. It also stated that around sixty percent
of patients having breast cancer get diagnosed in the late stages.
Bob Proulx, Executive
Chairman of Imagion Biosystems Limited, said that this patent grant is a
significant addition to their IP portfolio. He added that sadly, the cases of
cancer (particularly breast cancer) in India following the rest of the world
are continuously and rapidly growing. In nations like India, where the
diagnosis usually occurs at late stages, there is a remarkable opportunity to
impact the survival rates. Thus, their technology to detect disease at the
early stages without using radiation or invasive procedures appears to meet an
unmet need in the areas of cancer diagnosis and management.
The current focus of
ImagionBiosystems is on diagnostic imaging addressing a $2 billion market
globally. In the specific, the Imagion’s magnetic nanoparticles technology
looks emphasizing lung, breast, prostate, and ovarian cancers.
It is expected that
due to the large size of the population and its continuous growth, along with
the development of the new cancer diagnostic technology in India, the nation
will soon become a growing part of the addressable global market. For more
visit: https://www.trademarkmaldives.com
Don’t
forget to follow us on social media:
Contact - US
No comments:
Post a Comment